A LinkedIn post from Phantom Neuro describes remarks by Founder & CEO Connor Glass at the Montgomery Summit 2026, focusing on advances in neurotechnology and human–machine interaction. The post highlights the company’s Phantom X system, which is positioned as a minimally invasive interface that sits beneath the skin to capture muscle signals and translate them into control inputs for robotic systems.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, this approach is intended to make control of prosthetic limbs and robotic exoskeletons more intuitive, while avoiding brain or deep-nerve surgery. The emphasis on a scalable platform and naturalistic control may signal Phantom Neuro’s ambition to address broader markets in prosthetics and industrial or medical exoskeletons, potentially expanding its long-term revenue opportunity if clinical performance and reimbursement pathways are validated.
The LinkedIn content also references a patient registry and upcoming clinical opportunities, suggesting the company is moving further into human studies and data collection. For investors, progress in clinical validation and patient recruitment is likely to be a key de-risking factor, influencing future partnership potential with prosthetics manufacturers, robotics companies, and healthcare providers in the emerging neurotech and HMI segments.